AstraZeneca said on Friday the drug, Lynparza, was approved for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/7EZNwbB
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» U.S. FDA approves AstraZeneca-Merck's Lynparza to treat early-stage breast cancer
https://ift.tt/tqbuJ6R
No comments:
Post a Comment